Atria Investments Inc Sells 716 Shares of Natera, Inc. (NASDAQ:NTRA)

Atria Investments Inc lessened its stake in Natera, Inc. (NASDAQ:NTRA) by 8.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,691 shares of the medical research company’s stock after selling 716 shares during the quarter. Atria Investments Inc’s holdings in Natera were worth $976,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of NTRA. Itau Unibanco Holding S.A. acquired a new position in shares of Natera in the 2nd quarter valued at approximately $28,000. Quarry LP raised its position in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares in the last quarter. GAMMA Investing LLC lifted its stake in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the last quarter. Tobam acquired a new stake in shares of Natera in the 2nd quarter valued at $74,000. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of Natera in the 1st quarter valued at $83,000. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Natera stock opened at $146.06 on Monday. The firm has a market cap of $19.28 billion, a P/E ratio of -82.99 and a beta of 1.53. The stock’s 50 day moving average is $127.38 and its 200 day moving average is $115.76. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. Natera, Inc. has a one year low of $52.01 and a one year high of $167.79.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same quarter in the previous year, the company earned ($0.95) EPS. The company’s revenue for the quarter was up 63.9% on a year-over-year basis. As a group, research analysts expect that Natera, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent analyst reports. Craig Hallum upped their price objective on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. BTIG Research lifted their price target on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, August 9th. The Goldman Sachs Group upped their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Piper Sandler restated an “overweight” rating and issued a $150.00 target price on shares of Natera in a research report on Friday, September 13th. Finally, Morgan Stanley upped their price target on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $137.65.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 4,728 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $146.41, for a total transaction of $692,226.48. Following the transaction, the chief executive officer now owns 185,034 shares in the company, valued at $27,090,827.94. The trade was a 2.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gail Boxer Marcus sold 2,212 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now owns 19,386 shares of the company’s stock, valued at $3,073,262.58. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,821 shares of company stock valued at $4,776,878. 7.60% of the stock is currently owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.